Treatment for moderate to severe atopic dermatitis in alpine and moderate maritime climates differentially affects helper T cells and memory B cells in children

Allergic DiseasesT Cells

Associations of Th2, Th17, Treg cells and IgA+ memory B cells with atopic disease in children: the Generation R Study

Allergy.

Looman KIM, van Meel ER, Grosserichter-Wagener C, Vissers FJM, Klingenberg JH, De Jong NW, de Jongste JC, Pasmans SGMA, Duijts L, van Zelm MC, Moll HA

doi: 10.1111/all.14010.

Atopic Dermatitis

Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study

J Am Acad Dermatol.

Fishbein AB, Mueller K, Kruse L, Boor P, Sheldon S, Zee P, Paller AS

doi: 10.1016/j.jaad.2017.08.043.

Atopic Dermatitis

Dupilumab in the treatment of moderate-to-severe atopic dermatitis.

Expert Rev Clin Immunol.

Kraft M, Worm M

doi: 10.1080/1744666X.2017.

Atopic Dermatitis

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis

Am J Clin Dermatol.

Frampton JE, Blair HA

doi: 10.1007/s40257-018-0370-9.

Atopic Dermatitis

Dupilumab for Moderate-to-Severe Atopic Dermatitis

Skin Therapy Lett.

Vangipuram R, Tyring SK

Atopic Dermatitis

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials

J Am Assoc Nurse Pract

Tofte SJ, Papp K, Sadick N, Bohnert K, Simpson E, Thaçi D, Bieber T, Blauvelt A, Sofen H, Gooderham M, Chen Z, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Ardeleanu M

doi: 10.1097/JXX.

Atopic Dermatitis

Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

J Am Acad Dermatol.

Blauvelt A, Simpson EL, Tyring SK, Purcell LA, Shumel B, Petro CD, Akinlade B, Gadkari A, Eckert L, Graham NMH, Pirozzi G, Evans R

doi: 10.1016/j.jaad.2018.07.048.

T CellsRheumatoid Arthritis

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis

Rheumatology (Oxford).

Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, Semmelink JF, van der Laken CJ, Gerlag DM, Thurlings RM, Tak PP

doi: 10.1093/rheumatology/key428.

Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Lancet.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B

doi: 10.1016/

Related content

Associations of Th2, Th17, Treg cells and IgA+ memory B cells with atopic disease in children: the Generation R Study

Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study

Dupilumab in the treatment of moderate-to-severe atopic dermatitis.

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis

Dupilumab for Moderate-to-Severe Atopic Dermatitis

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials

Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial